메뉴 건너뛰기




Volumn 8, Issue 8, 2016, Pages 1015-1017

HDAC inhibitors with PD-1 blockade: A promising strategy for treatment of multiple cancer types?

Author keywords

clinical trial; epigenetic agents; histone deacetylase inhibitors; immunotherapy; lung cancer; PD 1; romidepsin; T cells; T cell chemokines; vorinostat

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; PDCD1 PROTEIN, HUMAN; ROMIDEPSIN;

EID: 84983294422     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi-2016-0066     Document Type: Review
Times cited : (22)

References (20)
  • 1
    • 84927130807 scopus 로고    scopus 로고
    • Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential
    • Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2), 205-214 (2015).
    • (2015) Cell , vol.161 , Issue.2 , pp. 205-214
    • Sharma, P.1    Allison, J.P.2
  • 2
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 3
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 5
    • 84880747672 scopus 로고    scopus 로고
    • Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance
    • Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1), 74-88 (2013).
    • (2013) Immunity , vol.39 , Issue.1 , pp. 74-88
    • Zitvogel, L.1    Galluzzi, L.2    Smyth, M.J.3    Kroemer, G.4
  • 7
    • 84862769116 scopus 로고    scopus 로고
    • An immune-active tumor microenvironment favors clinical response to ipilimumab
    • Ji RR, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61(7), 1019-1031 (2012).
    • (2012) Cancer Immunol. Immunother. , vol.61 , Issue.7 , pp. 1019-1031
    • Ji, R.R.1    Chasalow, S.D.2    Wang, L.3
  • 8
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014).
    • (2014) Nature , vol.515 , Issue.7528 , pp. 563-567
    • Herbst, R.S.1    Soria, J.C.2    Kowanetz, M.3
  • 9
    • 84969545536 scopus 로고    scopus 로고
    • HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma
    • (Epub ahead of print)
    • Zheng H, Zhao W, Yan C et al. HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-15-2584 (2016) (Epub ahead of print).
    • (2016) Clin. Cancer Res.
    • Zheng, H.1    Zhao, W.2    Yan, C.3
  • 10
    • 84878602787 scopus 로고    scopus 로고
    • Lung tumor NFkappaB signaling promotes T cell-mediated immune surveillance
    • Hopewell EL, Zhao W, Fulp WJ et al. Lung tumor NFkappaB signaling promotes T cell-mediated immune surveillance. J. Clin. Invest. 123(6), 2509-2522 (2013).
    • (2013) J. Clin. Invest. , vol.123 , Issue.6 , pp. 2509-2522
    • Hopewell, E.L.1    Zhao, W.2    Fulp, W.J.3
  • 11
    • 84882267461 scopus 로고    scopus 로고
    • Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer
    • Ma T, Galimberti F, Erkmen CP et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol. Cancer Ther. 12(8), 1545-1555 (2013).
    • (2013) Mol. Cancer Ther. , vol.12 , Issue.8 , pp. 1545-1555
    • Ma, T.1    Galimberti, F.2    Erkmen, C.P.3
  • 12
    • 84879657918 scopus 로고    scopus 로고
    • Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4
    • Burke SJ, Goff MR, Lu D, Proud D, Karlstad MD, Collier JJ. Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4. J. Immunol. 191(1), 323-336 (2013).
    • (2013) J. Immunol. , vol.191 , Issue.1 , pp. 323-336
    • Burke, S.J.1    Goff, M.R.2    Lu, D.3    Proud, D.4    Karlstad, M.D.5    Collier, J.J.6
  • 13
    • 84905994658 scopus 로고    scopus 로고
    • Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
    • Kim K, Skora AD, Li Z et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111(32), 11774-11779 (2014).
    • (2014) Proc. Natl Acad. Sci. USA , vol.111 , Issue.32 , pp. 11774-11779
    • Kim, K.1    Skora, A.D.2    Li, Z.3
  • 14
    • 72249084921 scopus 로고    scopus 로고
    • Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824
    • Vo DD, Prins RM, Begley JL et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 69(22), 8693-8699 (2009).
    • (2009) Cancer Res. , vol.69 , Issue.22 , pp. 8693-8699
    • Vo, D.D.1    Prins, R.M.2    Begley, J.L.3
  • 15
    • 79952760874 scopus 로고    scopus 로고
    • Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
    • Christiansen AJ, West A, Banks KM et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc. Natl Acad. Sci. USA 108(10), 4141-4146 (2011).
    • (2011) Proc. Natl Acad. Sci. USA , vol.108 , Issue.10 , pp. 4141-4146
    • Christiansen, A.J.1    West, A.2    Banks, K.M.3
  • 16
    • 84891276397 scopus 로고    scopus 로고
    • An intact immune system is required for the anticancer activities of histone deacetylase inhibitors
    • West AC, Mattarollo SR, Shortt J et al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res. 73(24), 7265-7276 (2013).
    • (2013) Cancer Res. , vol.73 , Issue.24 , pp. 7265-7276
    • West, A.C.1    Mattarollo, S.R.2    Shortt, J.3
  • 17
    • 84892942381 scopus 로고    scopus 로고
    • New and emerging HDAC inhibitors for cancer treatment
    • West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124(1), 30-39 (2014).
    • (2014) J. Clin. Invest. , vol.124 , Issue.1 , pp. 30-39
    • West, A.C.1    Johnstone, R.W.2
  • 18
    • 84946912433 scopus 로고    scopus 로고
    • Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
    • Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577), 249-253 (2015).
    • (2015) Nature , vol.527 , Issue.7577 , pp. 249-253
    • Peng, D.1    Kryczek, I.2    Nagarsheth, N.3
  • 19
    • 84920956732 scopus 로고    scopus 로고
    • PD-1 blockade induces responses by inhibiting adaptive immune resistance
    • Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568-571 (2014).
    • (2014) Nature , vol.515 , Issue.7528 , pp. 568-571
    • Tumeh, P.C.1    Harview, C.L.2    Yearley, J.H.3
  • 20
    • 84975063521 scopus 로고    scopus 로고
    • Differential association of STK11 and TP53 with KRAS mutationassociated gene expression, proliferation and immune surveillance in lung adenocarcinoma
    • (Epub ahead of print)
    • Schabath MB, Welsh EA, Fulp WJ et al. Differential association of STK11 and TP53 with KRAS mutationassociated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene doi:10.1038/onc.2015.375 (2015) (Epub ahead of print).
    • (2015) Oncogene
    • Schabath, M.B.1    Welsh, E.A.2    Fulp, W.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.